Related Jobs
-
RO and SRO - Hospital Products - Leading Generics
Job Type: Permanent
Salary: Salary on application
Location: England - Essex -
Regulatory Affairs Officer/Senior Regulatory Affairs Office
Job Type: Permanent
Salary: Salary on application
Location: England - Essex
EU approval for new diabetes drug
22 Nov 2006
Regulatory Affairs
Byetta (exenatide) has been approved to treat type two diabetes by the European Commission, according to Eli Lilly and Amlin Pharmaceuticals.
The two companies jointly developed the treatment, which the commission cleared after a positive opinion was issued by the Committee for Medicinal Products for Human Use.
Byetta will now be available as a treatment option for patients whose blood sugar levels have not been controlled by the maximum doses of either metformin, sulfonylurea or both.
"The availability of a treatment that lowers blood sugar to a healthy range, lowers weight, and has the potential to help restore the response of the body's insulin-producing cells is an exciting advance for patients with type two diabetes," said Professor Anthony Barnett from the University of Birmingham.
"Exenatide is an appropriate option to consider when patients cannot control their blood sugar using one or more oral medications," he added.
The companies intend to launch the drug on the European market next year, where there is believed to be in excess of 48 million people living with diabetes.
© Adfero Ltd
